DexCom, Inc. (NASDAQ:DXCM) Stock Position Decreased by Arthur M. Cohen & Associates LLC

Arthur M. Cohen & Associates LLC lowered its position in DexCom, Inc. (NASDAQ:DXCM) by 57.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,458 shares of the medical device company’s stock after selling 6,020 shares during the quarter. Arthur M. Cohen & Associates LLC’s holdings in DexCom were worth $294,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of DexCom by 0.3% in the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after purchasing an additional 136,282 shares during the period. Blair William & Co. IL increased its stake in shares of DexCom by 1.4% in the first quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company’s stock valued at $628,684,000 after purchasing an additional 64,683 shares during the period. Legal & General Group Plc increased its stake in shares of DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after purchasing an additional 49,076 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of DexCom by 16.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after acquiring an additional 353,019 shares in the last quarter. Finally, 1832 Asset Management L.P. boosted its holdings in shares of DexCom by 1.1% in the first quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company’s stock valued at $252,906,000 after acquiring an additional 20,400 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on DXCM shares. Royal Bank of Canada decreased their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Wells Fargo & Company increased their price objective on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Stifel Nicolaus increased their price objective on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Oppenheimer decreased their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Sanford C. Bernstein increased their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Trading Down 0.7 %

Shares of NASDAQ:DXCM traded down $0.50 during mid-day trading on Tuesday, hitting $69.20. The stock had a trading volume of 62,170 shares, compared to its average volume of 3,885,632. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The company has a market cap of $27.03 billion, a PE ratio of 41.74, a P/E/G ratio of 2.16 and a beta of 1.17. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company’s 50 day moving average is $69.77 and its 200-day moving average is $94.92.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other DexCom news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.